G51.F Genscript Biotech Corporation

Healthcare Biotechnology Frankfurt Exchange
3.40 EUR
Close of Nov 13, 2026
1.14 5.45
Market cap
EUR 7.75B
P/E
-
P/B
2.53x
ROE
-13.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is G51.F undervalued?

Graham number

The Graham number of Genscript Biotech Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genscript Biotech Corporation fundamental analysis

No fundamental analysis for Genscript Biotech Corporation yet.

Genscript Biotech Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genscript Biotech Corporation

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which ar…

Full company profile